Madrigal Pharmaceuticals, Inc. Insider Trading

MDGL

Last 12 months

Insiders sold $81.5M and bought nothing on the open market.

81% of the selling was scheduled in advance under 10b5-1 plans. Director Kenneth Bate sold $8.03M on Nov 5, 2025, 86% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$81.5M

0 buys · 28 sales

Under a 10b5-1 plan

81%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Aug 2025

Aug 18, 2025

Get an email when MDGL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 9 – 11	William John Sibold President and CEO	Sold10b5-1 plan 24 parts	11,583	$538.65 average	$6.24M	5.5%	Form 4
Aug 17	Shannon T Kelley General Counsel	SoldNo plan	664	$514.97	342K	5.5%	Form 4
Jul 20	William John Sibold President and CEO	SoldNo plan 10 parts	2,500	$547.30 average	$1.37M	1.2%	Form 4
Jun 1	David Soergel Chief Medical Officer	Sold10b5-1 plan	1,042	$495.74	517K	9.4%	Form 4
May 22	Richard S Levy Director	Sold10b5-1 plan 12 parts	5,682	$515.44 average	$2.93M	21%	Form 4
May 18	David Soergel Chief Medical Officer	SoldNo plan	844	$515.90	435K	7.1%	Form 4
Mar 6	Mardi Dier EVP and CFO	Sold10b5-1 plan 12 parts	1,982	$430.87 average	854K	14%	Form 4
Mar 6	William John Sibold President and CEO	SoldNo plan	1,663	$431.94	718K	1.0%	Form 4
Mar 6	Shannon T Kelley General Counsel	SoldNo plan	360	$431.94	155K	2.9%	Form 4
Mar 6	Carole Huntsman Chief Commercial Officer	SoldNo plan	419	$431.94	181K	3.2%	Form 4
Mar 6	Rebecca Taub Director	SoldNo plan	491	$431.94	212K	<0.1%	Form 4
Mar 2	Mardi Dier EVP and CFO	SoldNo plan	1,183	$427.21	505K	11%	Form 4
Jan 26	Carole Huntsman Chief Commercial Officer	Sold10b5-1 plan 2 parts	910	$493.78 average	449K	9.1%	Form 4
Jan 26	William John Sibold President and CEO	SoldNo plan	1,577	$492.42	777K	1.1%	Form 4
Jan 26	Rebecca Taub Director	SoldNo plan	647	$492.42	319K	<0.1%	Form 4
Jan 20	Shannon T Kelley General Counsel	Sold10b5-1 plan 2 parts	692	$497.36 average	344K	7.5%	Form 4
Jan 20	Rebecca Taub Director	SoldNo plan	2,238	$490.77	$1.1M	0.2%	Form 4
Jan 9	Paul A Friedman Director	Sold10b5-1 plan	280	$551.24	154K	<0.1%	Form 4
Jan 9	Paul A Friedman Director	Sold10b5-1 plan 28 parts	24,520	$522.39 average	$12.8M	2.8%	Form 4
Jan 9	Rebecca Taub Director	Sold10b5-1 plan 2 parts	240	$550.33 average	132K	<0.1%	Form 4
Jan 9	Rebecca Taub Director	Sold10b5-1 plan 28 parts	18,410	$522.40 average	$9.62M	1.6%	Form 4
Dec 10, 2025	Paul A Friedman Director	Sold10b5-1 plan 9 parts	24,800	$552.18 average	$13.7M	2.9%	Form 4
Dec 10, 2025	Rebecca Taub Director	Sold10b5-1 plan 9 parts	18,650	$552.15 average	$10.3M	1.7%	Form 4
Dec 4, 2025	William John Sibold President and CEO	SoldNo plan	2,400	$575.34	$1.38M	1.6%	Form 4
Dec 2, 2025	Mardi Dier EVP and CFO	Sold10b5-1 plan 15 parts	4,173	$578.34 average	$2.41M	29%	Form 4
Nov 21, 2025	Carole Huntsman Chief Commercial Officer	Sold10b5-1 plan 11 parts	1,958	$553.11 average	$1.08M	16%	Form 4
Nov 13, 2025	Richard S Levy Director	Sold10b5-1 plan 14 parts	8,500	$520.96 average	$4.43M	29%	Form 4
Nov 5, 2025	Kenneth Bate Director	SoldNo plan 11 parts	16,575	$484.31 average	$8.03M	86%	Form 4
Sep 9, 2025	William John Sibold President and CEO	SoldNo plan	7,279	$445.63	$3.24M	6.6%	Form 4
Aug 21, 2025	William John Sibold President and CEO	Sold10b5-1 plan 2 parts	7,616	$400.17 average	$3.05M	6.5%	Form 4
Aug 18, 2025 – Aug 20, 2025	Baker Bros. Advisors (gp) LLC Large holder	Bought 26 parts	97,065	$380.58 average	$36.9M	5.2%	Form 4
Aug 18, 2025	Felix Baker Director	Bought 28 parts	68,618	$364.04 average	$25M	3.8%	Form 4
Aug 18, 2025	Shannon T Kelley General Counsel	Sold10b5-1 plan 8 parts	1,304	$367.81 average	480K	12%	Form 4
Aug 15, 2025	Kenneth Bate Director	SoldNo plan 6 parts	10,000	$365.20 average	$3.65M	79%	Form 4
Aug 13, 2025	Paul A Friedman Director	Sold10b5-1 plan 17 parts	129,172	$370.24 average	$47.8M	13%	Form 4
Aug 11, 2025 – Aug 12, 2025	Rebecca Taub Director	Sold10b5-1 plan 12 parts	46,463	$355.31 average	$16.5M	4.0%	Form 4
Aug 11, 2025 – Aug 12, 2025	Paul A Friedman Director	Sold10b5-1 plan 12 parts	46,808	$355.31 average	$16.6M	5.3%	Form 4
Jul 18, 2025	Rebecca Taub Director	Sold10b5-1 plan	1,000	$350.01	350K	<0.1%	Form 4
Jul 18, 2025	Paul A Friedman Director	Sold10b5-1 plan	1,400	$350.03	490K	0.2%	Form 4
Jul 16, 2025 – Jul 17, 2025	Paul A Friedman Director	Sold10b5-1 plan 9 parts	28,876	$353.19 average	$10.2M	3.3%	Form 4

Sep 9 – 1110b5-1 plan
William John Sibold
President and CEO · sold 11,583 at avg $538.65
$6.24M
5.5% of stake
Aug 17No plan
Shannon T Kelley
General Counsel · sold 664 at $514.97
342K
5.5% of stake
Jul 20No plan
William John Sibold
President and CEO · sold 2,500 at avg $547.30
$1.37M
1.2% of stake
Jun 110b5-1 plan
David Soergel
Chief Medical Officer · sold 1,042 at $495.74
517K
9.4% of stake
May 2210b5-1 plan
Richard S Levy
Director · sold 5,682 at avg $515.44
$2.93M
21% of stake
May 18No plan
David Soergel
Chief Medical Officer · sold 844 at $515.90
435K
7.1% of stake
Mar 610b5-1 plan
Mardi Dier
EVP and CFO · sold 1,982 at avg $430.87
854K
14% of stake
Mar 6No plan
William John Sibold
President and CEO · sold 1,663 at $431.94
718K
1.0% of stake
Mar 6No plan
Shannon T Kelley
General Counsel · sold 360 at $431.94
155K
2.9% of stake
Mar 6No plan
Carole Huntsman
Chief Commercial Officer · sold 419 at $431.94
181K
3.2% of stake
Mar 6No plan
Rebecca Taub
Director · sold 491 at $431.94
212K
<0.1% of stake
Mar 2No plan
Mardi Dier
EVP and CFO · sold 1,183 at $427.21
505K
11% of stake
Jan 2610b5-1 plan
Carole Huntsman
Chief Commercial Officer · sold 910 at avg $493.78
449K
9.1% of stake
Jan 26No plan
William John Sibold
President and CEO · sold 1,577 at $492.42
777K
1.1% of stake
Jan 26No plan
Rebecca Taub
Director · sold 647 at $492.42
319K
<0.1% of stake
Jan 2010b5-1 plan
Shannon T Kelley
General Counsel · sold 692 at avg $497.36
344K
7.5% of stake
Jan 20No plan
Rebecca Taub
Director · sold 2,238 at $490.77
$1.1M
0.2% of stake
Jan 910b5-1 plan
Paul A Friedman
Director · sold 280 at $551.24
154K
<0.1% of stake
Jan 910b5-1 plan
Paul A Friedman
Director · sold 24,520 at avg $522.39
$12.8M
2.8% of stake
Jan 910b5-1 plan
Rebecca Taub
Director · sold 240 at avg $550.33
132K
<0.1% of stake
Jan 910b5-1 plan
Rebecca Taub
Director · sold 18,410 at avg $522.40
$9.62M
1.6% of stake
Dec 10, 202510b5-1 plan
Paul A Friedman
Director · sold 24,800 at avg $552.18
$13.7M
2.9% of stake
Dec 10, 202510b5-1 plan
Rebecca Taub
Director · sold 18,650 at avg $552.15
$10.3M
1.7% of stake
Dec 4, 2025No plan
William John Sibold
President and CEO · sold 2,400 at $575.34
$1.38M
1.6% of stake
Dec 2, 202510b5-1 plan
Mardi Dier
EVP and CFO · sold 4,173 at avg $578.34
$2.41M
29% of stake
Nov 21, 202510b5-1 plan
Carole Huntsman
Chief Commercial Officer · sold 1,958 at avg $553.11
$1.08M
16% of stake
Nov 13, 202510b5-1 plan
Richard S Levy
Director · sold 8,500 at avg $520.96
$4.43M
29% of stake
Nov 5, 2025No plan
Kenneth Bate
Director · sold 16,575 at avg $484.31
$8.03M
86% of stake
Sep 9, 2025No plan
William John Sibold
President and CEO · sold 7,279 at $445.63
$3.24M
6.6% of stake
Aug 21, 202510b5-1 plan
William John Sibold
President and CEO · sold 7,616 at avg $400.17
$3.05M
6.5% of stake
Aug 18, 2025 – Aug 20, 2025
Baker Bros. Advisors (gp) LLC
Large holder · bought 97,065 at avg $380.58
$36.9M
5.2% of stake
Aug 18, 2025
Felix Baker
Director · bought 68,618 at avg $364.04
$25M
3.8% of stake
Aug 18, 202510b5-1 plan
Shannon T Kelley
General Counsel · sold 1,304 at avg $367.81
480K
12% of stake
Aug 15, 2025No plan
Kenneth Bate
Director · sold 10,000 at avg $365.20
$3.65M
79% of stake
Aug 13, 202510b5-1 plan
Paul A Friedman
Director · sold 129,172 at avg $370.24
$47.8M
13% of stake
Aug 11, 2025 – Aug 12, 202510b5-1 plan
Rebecca Taub
Director · sold 46,463 at avg $355.31
$16.5M
4.0% of stake
Aug 11, 2025 – Aug 12, 202510b5-1 plan
Paul A Friedman
Director · sold 46,808 at avg $355.31
$16.6M
5.3% of stake
Jul 18, 202510b5-1 plan
Rebecca Taub
Director · sold 1,000 at $350.01
350K
<0.1% of stake
Jul 18, 202510b5-1 plan
Paul A Friedman
Director · sold 1,400 at $350.03
490K
0.2% of stake
Jul 16, 2025 – Jul 17, 202510b5-1 plan
Paul A Friedman
Director · sold 28,876 at avg $353.19
$10.2M
3.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MDGL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MDGL

CompareIntrinsic value

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

INSMInsmed Inc.

$110.00+5.32%40

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

ALKSAlkermes plc

$45.90+0.46%36

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

Held by ETFs

MDGL is in 86 US ETFs. The largest of them, with MDGL's weight in each:

Spot a number that looks wrong? Check it in MDGL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MDGL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.